Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1011081
Keywords
gamma delta T; immunotherapy; anticancer; intracellular; surveillance; clinical; chimeric antigen receptor; gamma delta (gamma delta) T cells
Categories
Funding
- Australian Research Council
- Axiom Healthcare Strategies, LLS (Princeton, NJ)
- [DE210100705]
- Australian Research Council [DE210100705] Funding Source: Australian Research Council
Ask authors/readers for more resources
This minireview explores the biology of gamma delta T cells, including their unique ability to recognize intracellular disturbances and non-peptide-based antigens, and proposes a framework for understanding gamma delta T cell-inspired therapeutic strategies in cancer treatment.
T cells play a key role in anticancer immunity, with responses mediated through a diversity of alpha beta or gamma delta T cell receptors. Although alpha beta and gamma delta T cells stem from common thymic precursors, the development and subsequent biological roles of these two subsets differ considerably. gamma delta T cells are an unconventional T cell subset, uniquely poised between the adaptive and innate immune systems, that possess the ability to recognize intracellular disturbances and non-peptide-based antigens to eliminate tumors. These distinctive features of gamma delta T cells have led to recent interest in developing gamma delta-inspired therapies for treating cancer patients. In this minireview, we explore the biology of gamma delta T cells, including how the gamma delta T cell immune surveillance system can detect intracellular disturbances, and propose a framework to understand the gamma delta T cell-inspired therapeutic strategies entering the clinic today.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available